Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.71 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.71 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL995610 | 1.00 | EGFR (0.71) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL1792662 | 1.00 | EGFR (0.71) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL15129030 | 0.91 | CISD1 (0.59) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL10058489 | 0.91 | CISD1 (0.59) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL10046554 | 0.91 | CISD1 (0.59) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL10058492 | 0.91 | CISD1 (0.59) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL12661978 | 0.91 | CISD1 (0.59) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL11941572 | 0.91 | CISD1 (0.59) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL4600830 | 0.90 | EGFR (0.85) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL10413058 | 0.90 | EGFR (0.85) | EGFRCISD1KDM4ESLC16A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4067367-B1 | OLEANANE CINNAMAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | LUNAN PHARMACEUTICAL GROUP CORP (CN) | 2025-05-28 | — | — | EP | disclosed |
| US-20230023332-A1 | OLEAN-PHENYLACRYLAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | LUNAN PHARMACEUTICAL GROUP CORPORATION (CN) | 2023-01-26 | — | — | US | disclosed |
| EP-4067367-A1 | OLEANANE CINNAMAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Lunan Pharmaceutical Group Corporation (CN) | 2022-10-05 | — | — | EP | disclosed |
| WO-2021104391-A1 | OLEANANE CINNAMAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 鲁南制药集团股份有限公司 | 2021-06-03 | — | — | WO | disclosed |
| EP-2270076-B1 | RESIN MOLDED PRODUCT AND POLYMER FILM | FUJIFILM CORP (JP) | 2018-05-23 | — | — | EP | disclosed |
| US-9481830-B2 | Cholesteric liquid crystal mixture, film, selective reflective plate, laminate, laminated glass | FUJIFILM CORPORATION (JP) | 2016-11-01 | — | — | US | disclosed |
| EP-2267067-B1 | Ultraviolet absorber composition and resin composition stabilized with the absorber composition | FUJIFILM CORP (JP) | 2015-08-12 | — | — | EP | disclosed |
| US-20140192286-A1 | CHOLESTERIC LIQUID CRYSTAL MIXTURE, FILM, SELECTIVE REFLECTIVE PLATE, LAMINATE, LAMINATED GLASS | FUJIFILM CORPORATION (JP) | 2014-07-10 | — | — | US | disclosed |
| US-8541488-B2 | Formed resin article and polymer film | FUJIFILM CORPORATION (JP) | 2013-09-24 | — | — | US | disclosed |
| US-8044123-B2 | Ultraviolet absorber composition and resin composition | FUJIFILM CORPORATION (JP) | 2011-10-25 | — | — | US | disclosed |
| EP-2267067-A1 | Ultraviolet absorber composition and resin composition stabilized with the absorber composition | Fujifilm Corporation (JP) | 2010-12-29 | — | — | EP | disclosed |
| US-20100324181-A1 | ULTRAVIOLET ABSORBER COMPOSITION AND RESIN COMPOSITION | FUJIFILM CORPORATION (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100004439-A1 | Heterocyclic Compound | FUJIFLM CORPORATION (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20090239982-A1 | Ultraviolet Absorbent and Heterocyclic Compound | FUJIFILM CORPORATION (JP) | 2009-09-24 | — | — | US | disclosed |
| US-4645735-A | ANTISTATIC | FUJI PHOTO FILM CO., LTD. (JP) | 1987-02-24 | — | — | US | disclosed |
| US-4551420-A | ULTRAVIOLET RAY ABSORBING POLYMER LATEX | FUJI PHOTO FILM CO., LTD. (JP) | 1985-11-05 | — | — | US | disclosed |
| US-4464463-A | FORMALDEHYDE-GAS SCAVENGER LOADED IN AN ULTRAVIOLET-ABSORBING ACRYLIC POLYMER LATEX | FUJI PHOTO FILM CO., LTD. (JP) | 1984-08-07 | — | — | US | disclosed |
| US-4464462-A | ULTRAVIOLET RAY-ABSORBING ACRYLIC POLYMER LATEX; ANTISTATIC AGENTS | FUJI PHOTO FILM CO., LTD. (JP) | 1984-08-07 | — | — | US | disclosed |
| US-4455368-A | Silver halide photographic light-sensitive material containing a UV absorbing polymer latex | FUJI PHOTO FILM CO., LTD. (JP) | 1984-06-19 | — | — | US | disclosed |
| US-4431726-A | WHICH IS A POLYMER LATEX | FUJI PHOTO FILM CO., LTD. (JP) | 1984-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023332-A1 | OLEAN-PHENYLACRYLAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | PAOX, ALOX12, PNMT | EGFR 4357/4885CISD1 2503/4885KDM4E 991/4885 |
| US-20090239982-A1 | Ultraviolet Absorbent and Heterocyclic Compound | CYP2A6, CYP2B6, XPO6 | EGFR 2374/4885CISD1 2698/4885KDM4E 2273/4885 |
| US-20100004439-A1 | Heterocyclic Compound | PTGER1, CYP1A1, ALOX12 | EGFR 4031/4885CISD1 964/4885KDM4E 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.